Drug-Drug Interaction
Drug-drug interaction studies play a critical role in evaluating how investigational therapies interact with other medications. CenExel supports sponsors with comprehensive DDI research programs designed to assess safety, pharmacokinetics, tolerability, and potential interaction risks in healthy volunteers and patient populations.
Studies Conducted
0
+
Trial Participants
0
+
Active Centers
0
Overview
Leading Drug-Drug Interaction Clinical Research
CenExel provides extensive expertise in designing and executing Drug-Drug Interaction (DDI) studies that support regulatory requirements and informed prescribing decisions. Our clinical pharmacology teams evaluate the effects of concomitant medications on drug absorption, metabolism, distribution, and elimination.
From early-phase development through post-marketing research, we deliver high-quality data that helps sponsors understand potential interactions, optimize dosing recommendations, and improve patient safety.
Our research capabilities include studies involving enzyme inhibition, enzyme induction, transporter interactions, and food-effect assessments.
Conditions Covered
Drug-Drug Interaction Studies We Support
Our research sites support a broad range of drug-drug interaction evaluations, including:
CYP450 Interaction Studies
Transporter Interaction Studies
Food Effect Studies
Pharmacokinetic (PK) Studies
Pharmacodynamic (PD) Studies
Drug-Metabolism Studies
Multiple-Dose Interaction Studies
Hepatic Impairment Studies
Renal Impairment Studies
Bioavailability & Bioequivalence Studies
Our Approach
Why Sponsors Choose CenExel for DDI Studies
Our acute pain expertise goes beyond patient enrollment — we deliver scientific insight, rapid execution, and reliable outcomes.
01
Rapid Study Start-Up
Our experienced teams enable fast site activation and efficient study execution for time-sensitive acute pain trials.
02
Diverse Surgical Models
We support multiple surgical indications, providing flexibility and robust patient recruitment.
03
Opioid-Sparing Focus
Expertise in evaluating non-opioid and multimodal pain management strategies.
04
High Enrollment Performance
Consistent delivery of strong enrollment through targeted recruitment strategies.
Phase Coverage
Supported Trial Phases
We support Drug-Drug Interaction studies across early development stages.
Active phases
Phase I
Phase II
Our early phase capabilities include pharmacodynamic biomarker strategies, first-in-human studies, and proof-of-concept trial design — guided by Chief Scientific Officer Dr. Larry Ereshefsky, an internationally recognized KOL in CNS research with over 30 years of early phase expertise.
Let’s Advance Your Next Study
Looking for an experienced clinical research partner with the expertise, capabilities, and reach to move your study forward? Connect with CenExel to discuss your needs and explore how our network can support your clinical development goals.
Explore Our Network
Discover CenExel’s Centers of Excellence and find the locations, therapeutic expertise, and capabilities that align with your clinical development needs.